Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status  Phase of research How it helps Latest publication
Suramin
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/05/2021
Anacardic acid
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/22/2021
Cleistanthin B
Potential treatment - pre-clinical evidence Natural product Antiviral Feb/25/2021
Diphyllin
Potential treatment - pre-clinical evidence Natural product Antiviral Feb/25/2021
Berberine
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/22/2021
GRL0617
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/20/2021
J08-MUT
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/23/2021
aly-miR396a-5p
Potential treatment - pre-clinical evidence Natural product Antiviral May/10/2021
VS12
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
Bis4
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/05/2021
Bis3
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/05/2021
Eicosapentaenoic acid
Potential treatment - pre-clinical evidence Natural product Antiviral Mar/04/2021
Calpain inhibitor II
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/01/2021
Linolenic acid
Potential treatment - pre-clinical evidence Natural product Antiviral Mar/04/2021
C2 (IgG)
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/15/2021
Hydroxyitraconazole
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/05/2021
VS10
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
7-chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/02/2021
2-((3,5-dichlorophenyl)amino)-5-hydroxyquinazolin-4 (3H)-one
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/02/2021
mAb 2-36
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/08/2021